| Literature DB >> 28415941 |
Yanbing Liang1, Xia Huang1, Yujie Jiang1, Yueqiu Qin1, Dingwei Peng1, Yuqing Huang1, Jin Li1, Suren R Sooranna2, Liao Pinhu1.
Abstract
Objective To examine the potential relationship of EPCR polymorphisms and the risk of sepsis in a Chinese population. Methods Snapshot SNP genotyping assays and DNA sequencing methods were used to detect polymorphisms of the EPCR gene, rs2069948C/T (2532C/T) and rs867186A/G (6936A/G), in 64 patients with sepsis and in 113 controls. Soluble EPCR (sEPCR) was measured by ELISA. Results There were significant differences in the allele and genotype frequencies of EPCR gene rs2069948C/T and allele frequencies of rs867186A/G between male and female patients and controls. Females carrying rs2069948 C/T genotype or T allele and males carrying rs867186 A allele were associated with a significantly increased risk of sepsis. Plasma sEPCR levels of sepsis patients were higher than controls and showed no correlation with EPCR gene polymorphisms. Conclusions EPCR polymorphisms may be associated with increased risk of sepsis, but this has no effect on the release of sEPCR in patients with sepsis.Entities:
Keywords: Endothelial protein C receptor; polymorphism; sepsis
Mesh:
Substances:
Year: 2017 PMID: 28415941 PMCID: PMC5536666 DOI: 10.1177/0300060516686496
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Characteristics of the 177 participations enrolled in the study.
| Parameter | Case (n = 64) | Controls (n = 113) | |
|---|---|---|---|
| Age (years) | 57.45 ± 15.80 | 55.34 ± 11.69 | 0.311 |
| Male | 38 | 82 | 0.071 |
| Female | 26 | 31 | |
| Site of infection | |||
| Lung | 32 | 0 | |
| Abdomen | 8 | 0 | |
| Blood | 3 | 0 | |
| Undefined site | 21 | 0 | |
| Co-morbidities | |||
| Diabetes | 7 | 0 | |
| Hypertension | 6 | 0 | |
| Renal dysfunction | 11 | 0 | |
| Liver dysfunction | 2 | 0 | |
| COPD | 1 | 0 | |
| ARDS | 3 | 0 | |
| Sepsis | 6 | 0 | |
| Sever sepsis | 17 | 0 | |
| Septic shock | 41 | 0 | |
| APACHE II score | 20.9 ± 6.9 | 0 |
Primer sequences used for detecting the different EPCR SNPs.
| SNP ID | Primer sequence |
|---|---|
| rs2069948 | F: 5′-CAGCCTCGAGGTAGGGGGTTAT-3′ |
| R: 5′-TGCAGCTGAATGATCGTGGTGT-3′ | |
| EF: 5′-TTTAGGCCTGCGGGCAGAGTCA-3′ | |
| rs867186 | F: 5′-ATGGACTCCTTGGGGGCCTATT-3′ |
| R: 5′-GTGGGCAGATGTGGGAGAAGAA-3′ | |
| EF: 5′-TTTTTTTTTTTTTTTTTTTTTCCACACCAGCAATGATGAAAC-3′ |
F: forward, R: reverse, E: extension.
Hardy-Weinberg equilibrium analysis.
| Actual genotype frequencies | Theoretical genotype frequencies | |||||||
|---|---|---|---|---|---|---|---|---|
| SNPs | CC | CT | TT | CC | CT | TT |
| |
| rs2069948C/T | 44 | 51 | 18 | 42.75 | 53.51 | 16.75 | 0.248 | 0.618 |
| AA | AG | AA | AG | |||||
| rs867186A/G | 94 | 19 | 94.8 | 17.4 | 0.952 | 0.329 | ||
Genotype and allele frequencies of EPCR gene in disease cases and controls.
| SNPs | Controls (%) | Cases (%) |
| OR (95%) | |
|---|---|---|---|---|---|
| rs2069948(C/T) | |||||
| CC | 44 (38.9) | 23 (35.9) | 1 | ||
| CT | 51 (45.1) | 31 (48.4) | 0.196 | 0.907 | 1.163 (0.593–2.280) |
| TT | 18 (15.9) | 10 (15.6) | 1.063 (0.422–2.675 | ||
| CCvsCT + TT | 69 (61.0) | 41 (64.0) | 0.156 | 0.693 | 1.137 (0.602–2.146) |
| TTvsCT + CC | 95 (84.0) | 54 (84.3) | 0.074 | 0.786 | 1.087 (0.594–1.991) |
| C | 139 (61.5) | 77(60.2) | |||
| T | 87 (38.5) | 51 (39.8) | 0.062 | 0.803 | 1.058 (0.679–1.649) |
| rs867186(A/G) | |||||
| AA | 94 (83.2) | 52 (81.2) | 1 | ||
| AG | 19 (16.8) | 11 (17.2) | 1.788 | 0.409 | 1.047 (0.463–2.367) |
| GG | 0 | 1 (1.6) | 1.019 (0.982–1.058) | ||
| AAvsAG + GG | 19 (16.8) | 12 (18.8) | 0.106 | 0.745 | 1.142 (0.514–2.536) |
| GGvsAG + AA | 113 (1) | 63 (98.4) | 0.001 | 0.973 | 1.008 (0.638–1.593) |
| A | 207 (91.6) | 115 (89.8) | 0.304 | 0.581 | 1.232 (0.587–2.585) |
| G | 19 (8.4) | 13 (10.2) |
rs2069948 CC and rs867186 AA were selected as the control group.
The distribution of genotype and allele frequencies of the EPCR gene SNPs in the sepsis group.
| Genotype frequencies (%) | Allele frequencies (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SNPs | n | CC | CT | TT |
| C | T |
| ||
| rs2069948(C/T) | ||||||||||
| male | 38 | 18 (47.37) | 16 (42.10) | 4 (10.53) | 52 (68.4) | 24 (31.6) | ||||
| female | 26 | 5 (19.23) | 15 (57.69) | 6 (23.08) | 5.732 | 0.057 | 25 (48.1) | 27 (51.9) | 5.331 | 0.021 |
| total | 64 | 23 (35.94) | 31 (48.44) | 10 (15.62) | 77 (60.16) | 51 (39.84) | ||||
| rs867186(A/G) | AA | AG | GG | A | G | |||||
| male | 38 | 34 (89.47) | 4 (10.53) | 0 | 72 (94.7) | 4 (5.3) | ||||
| female | 26 | 18 (69.23) | 7 (26.92) | 1 (3.85) | 4.655 | 0.098 | 43 (84.3) | 9 (15.7) | 4.909 | 0.027 |
| total | 64 | 52 (81.25) | 11 (17.19) | 1 (1.56) | 115 (89.84) | 13 (10.16) | ||||
Comparison of genotype and allele frequencies between males and females with sepsis and control group.
| SNPs | Sex | Controls (%) | Cases (%) |
| OR (95% CI) | Adjusted OR (95% CI) |
|---|---|---|---|---|---|---|
| rs2069948C/T | ||||||
| CC | male | 32 (39.03) | 18 (47.37) | 0.244 | 0.741 (0.225–2.441) | 0.698 (0.208–2.340) |
| female | 12 (38.71) | 5 (19.23) | ||||
| CT | male | 38 (46.34) | 16 (42.11) | 4.495 | 2.740 (1.065–7.050) | 2.763 (1.051–7.264) |
| female | 13 (41.94) | 15 (57.69) | ||||
| TT | male | 12 (14.63) | 4 (10.52) | 0.937 | 3 (0.606–14.864) | 2.748 (0.516–14.649) |
| female | 6 (19.35) | 6 (23.08) | ||||
| C | male | 102 (62.20) | 52 (68.42) | 0.828 | 1.325 (0.722–2.433) | – |
| female | 37 (59.68) | 25 (48.08) | ||||
| T | male | 62 (37.80) | 24 (31.58) | 8.022 | 2.790 (1.358–5.730) | – |
| female | 25 (40.32) | 27 (51.92) | ||||
| rs867186(A/G) | ||||||
| AA | male | 72 (87.80) | 34 (89.47) | 2.116 | 1.733 (0.823–3.648) | 1.752 (0.830–3.698) |
| female | 22 (70.97) | 18 (69.23) | ||||
| AG | male | 10 (12.20) | 4 (10.53) | 0.741 | 1.944 (0.424–8.919) | 1.844 (0.394–8.628) |
| female | 9 (29.03) | 7 (26.92) | ||||
| GG | male | 0 | 0 | – | – | – |
| female | 0 | 1 (3.85) | ||||
| A | male | 154 (93.90) | 72 (94.74) | 4.909 | 1.735 (1.063–2.833) | – |
| female | 53 (85.48) | 43 (82.69) | ||||
| G | male | 10 (6.10) | 4 (5.26) | 1.499 | 2.500 (0.568–11.011) | – |
| female | 9 (14.52) | 9 (17.31) | ||||